MRI INTERVENTIONS, INC. (OTCMKTS:MRIC) Files An 8-K Termination of a Material Definitive Agreement

MRI INTERVENTIONS, INC. (OTCMKTS:MRIC) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02. Termination of Material Definitive Agreement.

Story continues below

On September 25, 2018, MRI Interventions, Inc. (the “Company”) (a)repaid in full all outstanding debt, together with interest and all other amounts due in connection with such repayment, under that certain Second Amended and Restated 5.5% Promissory Note, Due December 31, 2018, issued to Brainlab AG (the “Brainlab Note”) and (b)terminated that certain Master Security Agreement dated April 5, 2011 by and between the Company and Brainlab AG.

In connection with the foregoing, the Company repaid a total of approximately $2.026 million, which included principal and interest. Effective upon receipt of such payment, the Brainlab Note and other related loan documents were terminated and are of no further force or effect (except with respect to any obligations and provisions that survive the termination thereof) and all liens granted in connection with the Brainlab Note and other related loan documents were released.

Item 3.03. Material Modification to Rights of Security Holders.

On September 25, 2018, the Company entered into a third amendment (the “Third Omnibus Amendment”) with respect to the Company’s 12% Second-Priority Secured Non-Convertible Promissory Notes Due 2019 (as amended and reissued from time to time, collectively, the “Notes”) having an aggregate principal balance of approximately $2 million. to the Third Omnibus Amendment, the Company and the holder of Notes representing a majority of the aggregate principal balance of the Notes agreed to extend the maturity date of all Notes by 18 months to September 2020.

The foregoing description of the Third Omnibus Amendment is only a summary and is qualified in its entirety by the full text of the Third Omnibus Amendment, the form of which is filed as Exhibit 10.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On September 25, 2018, the Company issued a press release announcing the repayment of the Brainlab Note and the amendment to the Notes. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information, including the press release, furnished under this Item 7.01 shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statements and Exhibits.


EX-10.1 2 ex10-1.htm THIRD OMNIBUS AMENDMENT   Exhibit 10.1   THIRD OMNIBUS AMENDMENT   THIS THIRD OMNIBUS AMENDMENT (this “Amendment”) is effective as of September 25,…
To view the full exhibit click here

An ad to help with our costs